Option chain shows key data for Silexion Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Silexion Therapeutics.

Silexion Therapeutics (NASDAQ:SLXN) Stock, Option Chain

Silexion Therapeutics

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

ASTL

BMGL

BNAI

BNTX

BPMC

BSII

CLEU

FAAS

LOGC

LUCD

LYRA

RSLS

SBET

SLXN

TIRX

VERA

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket

Collaborating on Research

Biotech

News

Health Care

Movers

Trading Ideas

General

Silexion&#39;s SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.

Silexion Therapeutics&#39; Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Lattice Semiconductor

Pre-Market Outlook

Markets

ACLS

AMKR

BHAT

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

TANH

VSTE

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

Press Releases

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Earnings

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

CEL-SCI

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Genprex

IN8bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

PharmaCyte Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Turnstone Biologics

Xenetic Biosciences

Maxim Group

Comments

Silexion Therapeutics

Silexion Therapeutics (SLXN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell